Stereotactic radiosurgery (SRS) is the standard of care treatment for patients with limited brain metastases; however radiation necrosis can develop. Standard clinical approaches have limited ability in differentiating radiation-induced changes from tumor progression. This work examines the performance of CEST metrics (MTRAmide and MTRrNOE) at 3T for differentiating radiation necrosis from tumor progression, extending a previous study to include higher saturation power (using B1=2.0μT) with added multivariable logistic regression. Results in 24 lesions showed that both saturation powers (0.52μT and 2.0μT) could distinguish tumor progression from radiation necrosis, with the MTRAmide(0.52μT) parameter selected from multivariable modelling with AUC=0.91.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords